Dyslipidemia

Announced on August 24, rivaroxaban (Xarelto) has received its ninth indication from the US FDA. This time, the FDA has approved a label expansion to include patients with symptomatic peripheral artery disease who have undergone lower extremity revascularization.

Pictorial data on carotid intima-media thickness and presence of carotid plaques can improve prescription of lipid-lowering drugs.

Using propensity score-matching, a new study is providing insight into the risk reduction and bleeding risk associated with various DOACs versus warfarin and one another in patients with nonvalvular atrial fibrillation and an increased gastrointestinal bleeding risk.

A trio of trials examine whether or not heparin could provide relief of COVID-19 symptoms in patients with varying levels of disease severity.

Data show the change in 24-hour ambulatory systolic blood pressure was significant between treatment and control groups with a reduction of 7.1 mm Hg.

Marc Bonaca, MD discusses the personalization of treatment in PAD patients, lack of proper research into the condition, and optimizing delivery of care.

Peter Toth, MD discusses the combination treatment aspects of lipid management agents, as well as the effect of the COVID-19 pandemic on cardiovascular care.

Peter Toth, MD, discusses the movement towards new agents in treatment of lipid management.

There are several cholesterol lowering drugs available for this patient population.

An analysis of data from the COMPASS study suggests the addition of low-dose rivaroxaban to aspirin resulted in benefits, irrespective of concomitant therapies or comorbidities.

Novartis announced the Complete Response resubmission for inclisiran in a statement on July 6, 2021.

An analysis of data from an RCT suggests statin use does not negatively impact the neurocognitive health or memory of older patients.

The FDA has granted approval to dabigatran etexilate (Pradaxa) for treatment of blood clots in pediatric patients with VTE and prevention of recurrent blood clots in those who have completed treatment for VTE.

Analysis of 2-year data from the GOULD Registry indicates new strategies are needed to address the suboptimal levels of lipid-lowering therapy intensification among patients with ASCVD and increased LDL-C.

The AHA has released a scientific statement highlighting the importance of prescribing physical activity as a first-line treatment in patient populations with elevated blood pressure or elevated cholesterol.

An analysis of patient and clinician responses to surveys within BOAT-AF suggests many were willing to consider DOACs but were never prescribed anticoagulation and also provides insight into how trends in this cohort compared to those in the ACC's PINNACLE registry.

A pooled risk simulation of phase 3 data of bempedoic acid suggests the first-in-class ATP citrate lyase inhibitor could reduce risk of cardiovascular events in patients with established cardiovascular disease and elevated LDL-C.

The TALOS AMI study suggests DAPT de-escalation 30 days after PCI was associated with lower rates of bleeding and the study's composite endpoint of cardiovascular death, MI, or stroke.

As part of our coverage of ACC.21, Practical Cardiology reached out to Deepak Bhatt, MD, MPH, to learn about his reaction to the latest analysis of the STRENGTH trial and how it might impact how REDUCE-IT results are interpreted.

A secondary analysis of the STRENGTH trial from ACC.21 is calling into question the apparent CV benefits of other fish oil-based agents in patients with elevated triglycerides.

The ADAPTABLE study from DCRI suggests patients with existing CVD saw similar outcomes whether they were receiving 81 mg or 325 mg aspirin, but also suggests patients with the higher dose were more likely to discontinue therapy.

There was no significant association between uric acid levels and incident stroke.

The latest study from Penn Medicine's Nudge Unit is detailing the impact of time of appointment on the probability of receiving a prescription for statin therapy at primary care clinics among patients with an indication for statin therapy.

In this column, Dr. Paul Thompson provides an account of a recent conversation with a colleague related to the potential for tendon issues, including tendon rupture, in a patient on statin therapy.

Bempedoic acid monotherapy and its combination with ezetimibe for lipid lowering in patients intolerant to statins.